Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) FCF Margin (2020 - 2025)

Journey Medical (DERM) has disclosed FCF Margin for 5 consecutive years, with 14.0% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin fell 609.0% year-over-year to 14.0%, compared with a TTM value of 6.69% through Sep 2025, up 6618.0%, and an annual FY2024 reading of 42.98%, down 4338.0% over the prior year.
  • FCF Margin was 14.0% for Q3 2025 at Journey Medical, down from 6.28% in the prior quarter.
  • Across five years, FCF Margin topped out at 387.61% in Q4 2023 and bottomed at 82.06% in Q1 2022.
  • Average FCF Margin over 5 years is 6.44%, with a median of 18.04% recorded in 2022.
  • The sharpest move saw FCF Margin soared 41171bps in 2023, then tumbled -37128bps in 2024.
  • Year by year, FCF Margin stood at 18.3% in 2021, then plummeted by -32bps to 24.09% in 2022, then surged by 1709bps to 387.61% in 2023, then crashed by -96bps to 16.34% in 2024, then tumbled by -186bps to 14.0% in 2025.
  • Business Quant data shows FCF Margin for DERM at 14.0% in Q3 2025, 6.28% in Q2 2025, and 21.55% in Q1 2025.